Novo Nordisk (NYSE:NVO) presented exploratory analyses from the STEP UP program showing that Wegovy (semaglutide) was associated with reductions in liver fat among adults with obesity who did not have diabetes.
Cardinal Health (NYSE:CAH) entered into a binding letter of intent with CVS Health to extend their existing pharmaceutical distribution agreement through June 30, 2032.
Agomab (NASDAQ:AGMB) reported topline results from the STENOVA open-label extension study of ontunisertib in patients with fibrostenosing Crohn’s disease, with 49 patients completing the 48-week extension period.
Shattuck Labs (NASDAQ:STTK) announced plans to evaluate SL-325 in a Phase 2 clinical trial for patients with moderate to severe hidradenitis suppurativa (HS), expanding the program beyond its existing inflammatory bowel disease development.
Eli Lilly (NYSE:LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing Foundayo was associated with lower modeled 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight.
United Therapeutics (NASDAQ:UTHR) announced that a Delaware federal court found Liquidia’s Yutrepia infringes two claims of a patent covering inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Regeneron (NASDAQ:REGN) expanded its antibody alliance with Sanofi through an agreement covering four long-acting antibody candidates and a $1 billion upfront payment to Regeneron.
Oculis (NASDAQ:OCS) joined the National Multiple Sclerosis Society’s Campaign to End MS as an industry partner focused on advancing research and care related to vision problems in multiple sclerosis.
Pfizer (NYSE:PFE) reported Phase 2 results showing that investigational tilrekimig achieved its primary endpoint by producing statistically significant increases in EASI-75 responses compared with placebo at Week 16 in adults with moderate-to-severe atopic dermatitis.
United Therapeutics (NASDAQ:UTHR) shares rose 13% to $543.99 after a Delaware federal court denied Liquidia’s motion to strike a defense argument in a patent infringement case involving Tyvaso and Yutrepia.
Tiziana Life Sciences (NASDAQ:TLSA) submitted a request to the U.S. Food and Drug Administration for Orphan Drug Designation for intranasal foralumab as a potential treatment for multiple system atrophy (MSA).
Kailera Therapeutics (NASDAQ:KLRA) announced completion of enrollment across three global Phase 3 trials evaluating investigational once-weekly ribupatide injection in people with obesity or overweight.
